Patents by Inventor Bengt Gustavsson

Bengt Gustavsson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190240224
    Abstract: The present invention provides methods for increasing plasma dUrd levels comprising the administration of 6R-MTHF. The methods of increasing plasma dUrd increase dUrd levels compared to equimolar concentrations of LV. The present invention also provides methods for increasing TS inhibition comprising the administration of 6R-MTHF. The present invention also provides methods for increasing TS inhibition comprising the administration of 6R-MTHF.
    Type: Application
    Filed: February 4, 2019
    Publication date: August 8, 2019
    Inventors: Göran U. Carlsson, Bengt Gustavsson, Elisabeth Odin, Yvonne Wettergren, Anders Vedin
  • Patent number: 10367677
    Abstract: Methods and apparatus in a fifth-generation wireless communications network, including an example method, in a wireless device, that includes determining a reporting quality threshold for a parameter related to channel state information (CSI); performing a measurement for each of a plurality of beams from a first predetermined set of beams for evaluation; evaluating the measurement for each of the plurality of beams against the reporting quality threshold; discontinuing the performing and evaluating of measurements in response to determining that the reporting quality threshold is met for one of the beams, such that one or more beams in the first predetermined set of beams are not measured and evaluated; and reporting, to the wireless communications network, CSI for the one of the beams.
    Type: Grant
    Filed: May 13, 2016
    Date of Patent: July 30, 2019
    Assignee: Telefonaktiebolaget LM Ericsson (publ)
    Inventors: Stefan Parkvall, Janne Peisa, Gunnar Mildh, Robert Baldemair, Stefan Wager, Jonas Kronander, Karl Werner, Richard Abrahamsson, Ismet Aktas, Peter Alriksson, Junaid Ansari, Shehzad Ali Ashraf, Henrik Asplund, Fredrik Athley, Håkan Axelsson, Joakim Axmon, Johan Axnäs, Kumar Balachandran, Gunnar Bark, Jan-Erik Berg, Andreas Bergström, Håkan Björkegren, Nadia Brahmi, Cagatay Capar, Anders Carlsson, Andreas Cedergren, Mikael Coldrey, Icaro L. J. da Silva, Erik Dahlman, Ali El Essaili, Ulrika Engström, Mårten Ericson, Erik Eriksson, Mikael Fallgren, Rul Fan, Gabor Fodor, Pål Frenger, Jonas Fridén, Jonas Fröberg Olsson, Anders Furuskár, Johan Furuskog, Virgile Garcia, Ather Gattami, Fredrik Gunnarsson, Ulf Gustavsson, Bo Hagerman, Fredrik Harrysson, Ning He, Martin Hessler, Kimmo Hiltunen, Songnam Hong, Dennis Hui, Jörg Huschke, Tim Irnich, Sven Jacobsson, Niklas Jaldén, Simon Järmyr, Zhiyuan Jiang, Martin Johansson, Niklas Johansson, Du Ho Kang, Eleftherios Karipidis, Patrik Karlsson, Ali S. Khayrallah, Caner Kilinc, Göran N. Klang, Sara Landström, Christina Larsson, Gen Li, Bo Lincoln, Lars Lindbom, Robert Lindgren, Bengt Lindoff, Fredrik Lindqvist, Jinhua Liu, Thorsten Lohmar, Qianxi Lu, Lars Manholm, Ivana Maric, Jonas Medbo, Qingyu Miao, Reza Moosavi, Walter Müller, Elena Myhre, Johan Nilsson, Karl Norrman, Bengt-Erik Olsson, Torgny Palenius, Sven Petersson, Jose Luis Pradas, Mikael Prytz, Olav Queseth, Pradeepa Ramachandra, Edgar Ramos, Andres Reial, Thomas Rimhagen, Emil Ringh, Patrik Rugeland, Johan Rune, Joachim Sachs, Henrik Sahlin, Vidit Saxena, Nima Seifi, Yngve Selén, Eliane Semaan, Sachin Sharma, Cong Shi, Johan Sköld, Magnus Stattin, Anders Stjernman, Dennis Sundman, Lars Sundström, Miurel Isabel Tercero Vargas, Claes Tidestav, Sibel Tombaz, Johan Torsner, Hugo Tullberg, Jari Vikberg, Peter Von Wrycza, Thomas Walldeen, Anders Wallén, Pontus Wallentin, Hai Wang, Ke Wang Helmersson, Jianfeng Wang, Yi-Pin Eric Wang, Niclas Wiberg, Emma Wittenmark, Osman Nuri Can Yilmaz, Ali Zaidi, Zhan Zhang, Zhang Zhang, Yanil Zheng
  • Patent number: 10328079
    Abstract: The present invention relates to the treatment of solid tumors in humans such as cancer, especially colorectal cancer (CRC), which involves administering multiple boluses of the diastereomerically pure folate adjuvant [6R]-5,10-methylenetetrahydrofolate in 5-fluorouracil (5-FU) based chemotherapy.
    Type: Grant
    Filed: January 9, 2018
    Date of Patent: June 25, 2019
    Assignee: Isofol Medical AB
    Inventors: Per L. Lindberg, Anders Vedin, Gunnel E. Sundén, Bengt Gustavsson
  • Patent number: 10292984
    Abstract: The present invention provides methods for increasing plasma dUrd levels comprising the administration of 6R-MTHF. The methods of increasing plasma dUrd increase dUrd levels compared to equimolar concentrations of LV. The present invention also provides methods for increasing TS inhibition comprising the administration of 6R-MTHF. The present invention also provides methods for increasing TS inhibition comprising the administration of 6R-MTHF.
    Type: Grant
    Filed: February 9, 2018
    Date of Patent: May 21, 2019
    Assignee: Isofol Medical AB
    Inventors: Göran U. Carlsson, Bengt Gustavsson, Elisabeth Odin, Yvonne Wettergren, Anders Vedin
  • Publication number: 20190060315
    Abstract: The present invention relates to the treatment of solid tumors in humans such as cancer, especially colorectal cancer (CRC), which involves administering multiple boluses of the diastereomerically pure folate adjuvant [6R]-5,10-methylenetetrahydrofolate in 5-fluorouracil (5-FU) based chemotherapy.
    Type: Application
    Filed: January 9, 2018
    Publication date: February 28, 2019
    Inventors: Per L. Lindberg, Anders Vedin, Gunnel E. Sundén, Bengt Gustavsson
  • Publication number: 20190060316
    Abstract: The present invention relates to the treatment of solid tumors in humans such as cancer, especially colorectal cancer (CRC), which involves administering the diastereomerically pure folate adjuvant [6R]-5,10-methylenetetrahydrofolate in 5-fluorouracil (5-FU) based chemotherapy.
    Type: Application
    Filed: January 9, 2018
    Publication date: February 28, 2019
    Inventors: Per L. Lindberg, Anders Vedin, Gunnel E. Sundén, Bengt Gustavsson
  • Publication number: 20180289711
    Abstract: The present invention provides methods for increasing plasma dUrd levels comprising the administration of 6R-MTHF. The methods of increasing plasma dUrd increase dUrd levels compared to equimolar concentrations of LV. The present invention also provides methods for increasing TS inhibition comprising the administration of 6R-MTHF. The present invention also provides methods for increasing TS inhibition comprising the administration of 6R-MTHF.
    Type: Application
    Filed: February 9, 2018
    Publication date: October 11, 2018
    Inventors: Göran U. Carlsson, Bengt Gustavsson, Elisabeth Odin, Yvonne Wettergren, Anders Vedin
  • Patent number: 9675617
    Abstract: The present invention relates a pharmaceutical composition comprising an EGFR inhibitor and methylene-tetrahydrofolate, tetrahydrofolate or methyl-tetrahydrofolate, for use in the treatment of cancer. The methylene-tetrahydrofolate, tetrahydrofolate or methyl-tetrahydrofolate enhances the anticancer efficacy of the EGFR inhibitor. The cancers that may be treated include breast cancer, gastric cancer, gastrointestinal cancer, gall bladder cancer, bile duct cancer, colon cancer, rectal cancer, liver cancer, pancreatic cancer, head and neck cancer, esophageal cancer, mesothelioma cancer, lung cancer including non-small-cell lung cancer, ovarian cancer, endometrial cancer, cervical cancer, peripheral T-cell lymphoma (PTCL), melanoma, brain tumors, adenocarcinoma, esophageal cancer, and osteosarcoma.
    Type: Grant
    Filed: January 18, 2013
    Date of Patent: June 13, 2017
    Assignee: ISOFOL MEDICAL AB
    Inventors: Bengt Gustavsson, Björn Carlsson
  • Patent number: 9585888
    Abstract: The use of tetrahydrofolate, methylene-tetrahydrofolate and/or methyl-tetrahydrofolate, and at least one multi-targeting antifolate, for the manufacture of a pharmaceutical composition for the treatment of cancer is disclosed. By combining the multi-targeting antifolate with tetrahydrofolate, methylene-tetrahydrofolate and/or methyl-tetrahydrofolate, it is possible to remarkably reduce toxic side-effects without diminishing the anti-tumor action of the drugs. A pharmaceutical composition, a kit comprising the pharmaceutical composition as well as a method for the treatment of cancer are also disclosed.
    Type: Grant
    Filed: July 29, 2015
    Date of Patent: March 7, 2017
    Assignee: ISOFOL MEDICAL AB
    Inventors: Bengt Gustavsson, Göran Carlsson
  • Publication number: 20150328218
    Abstract: The use of tetrahydrofolate, methylene-tetrahydrofolate and/or methyl-tetrahydrofolate, and at least one multi-targeting antifolate, for the manufacture of a pharmaceutical composition for the treatment of cancer is disclosed. By combining the multi-targeting antifolate with tetrahydrofolate, methylene-tetrahydrofolate and/or methyl-tetrahydrofolate, it is possible to remarkably reduce toxic side-effects without diminishing the anti-tumour action of the drugs. A pharmaceutical composition, a kit comprising the pharmaceutical composition as well as a method for the treatment of cancer are also disclosed.
    Type: Application
    Filed: July 29, 2015
    Publication date: November 19, 2015
    Inventors: Bengt GUSTAVSSON, Göran CARLSSON
  • Patent number: 9138435
    Abstract: The use of tetrahydrofolate, methylene-tetrahydrofolate and/or methyl-tetrahydrofolate, and at least one multi-targeting antifolate, for the manufacture of a pharmaceutical composition for the treatment of cancer is disclosed. By combining the multi-targeting antifolate with tetrahydrofolate, methylene-tetrahydrofolate and/or methyl-tetrahydrofolate, it is possible to remarkably reduce toxic side-effects without diminishing the anti-tumor action of the drugs. A pharmaceutical composition, a kit comprising the pharmaceutical composition as well as a method for the treatment of cancer are also disclosed.
    Type: Grant
    Filed: July 22, 2010
    Date of Patent: September 22, 2015
    Assignee: ISOFOL MEDICAL AB
    Inventors: Bengt Gustavsson, Göran Carlsson
  • Publication number: 20150017158
    Abstract: The present invention relates a pharmaceutical composition comprising an EGFR inhibitor and methylene-tetrahydrofolate, tetrahydrofolate or methyl-tetrahydrofolate, for use in the treatment of cancer. The methylene-tetrahydrofolate, tetrahydrofolate or methyl-tetrahydrofolate enhances the anticancer efficacy of the EGFR inhibitor.
    Type: Application
    Filed: January 18, 2013
    Publication date: January 15, 2015
    Applicant: ISOFOL MEDICAL AB
    Inventors: Bengt Gustavsson, Björn Carlsson
  • Publication number: 20150018361
    Abstract: The present invention relates to methylene-tetrahydrofolate for use in the treatment of cancer, based on its intrinsic antitumor activity. The cancers that may be treated include breast cancer, gastric cancer, gastrointestinal cancer, gall bladder cancer, bile duct cancer, colon cancer, rectal cancer, liver cancer, pancreatic cancer, head and neck cancer, esophageal cancer, mesothelioma cancer, lung cancer including non-small-cell lung cancer, ovarian cancer, endometrial cancer, cervical cancer, peripheral cell lymphoma (PTCL), melanoma, brain tumors, adenocarcinoma, esophageal cancer, and osteosarcoma.
    Type: Application
    Filed: January 18, 2013
    Publication date: January 15, 2015
    Applicant: ISOFOL MEDICAL AB
    Inventors: Bengt Gustavsson, Björn Carlsson
  • Patent number: 8539678
    Abstract: A device for a motor driven tool such as a pole hedge trimmer, a pole saw or the like. The tool includes a drive unit that via a shaft tube is connected to a cutting unit. The cutting unit is turnably secured at the shaft tube by the device which is a turnable connection, wherein the cutting unit is movable between a range of at least two working positions and a transport position. The cutting unit is provided with one or several movable cutting elements and the tool is provided with locking structure for locking the movement of the cutting elements when the cutting unit is in the transport position.
    Type: Grant
    Filed: April 28, 2005
    Date of Patent: September 24, 2013
    Assignee: Husqvarna AB
    Inventors: Goran Dahlberg, Bengt Gustavsson
  • Publication number: 20100311762
    Abstract: The use of tetrahydrofolate, methylene-tetrahydrofolate and/or methyl-tetrahydrofolate, and at least one multi-targeting antifolate, for the manufacture of a pharmaceutical composition for the treatment of cancer is disclosed. By combining the multi-targeting antifolate with tetrahydrofolate, methylene-tetrahydrofolate and/or methyl-tetrahydrofolate, it is possible to remarkably reduce toxic side-effects without diminishing the anti-tumour action of the drugs. A pharmaceutical composition, a kit comprising the pharmaceutical composition as well as a method for the treatment of cancer are also disclosed.
    Type: Application
    Filed: July 22, 2010
    Publication date: December 9, 2010
    Inventors: Bengt Gustavsson, Göran Carlsson
  • Publication number: 20070283799
    Abstract: Apparatuses, methods and computer program products involving playing music by means of portable communication apparatuses, e.g. mobile telephones, as instruments. According to an embodiment of the invention, a method for generating music data in a portable communication apparatus is provided. A first stream of music data from a first music data generator and a second stream of music data from a second music data generator are received by means of a mixer device of the portable communication apparatus. Furthermore, the first and the second streams of music data are mixed to a third stream of music data. The third stream of music data is fed to a music data player of the portable communication apparatus for playing the third stream of music data.
    Type: Application
    Filed: October 3, 2006
    Publication date: December 13, 2007
    Applicant: SONY ERICSSON MOBILE COMMUNICATIONS AB
    Inventors: Carl Andrew Carruthers, Stefan Bengt Gustavsson, Magnus Fredrik Hansson
  • Publication number: 20070258480
    Abstract: The invention relates to a resource management system and method for handling of devices with features incorporated in an apparatus, such as a mobile telephone, but implemented as separate entities and controlled through interfaces. The resource management system includes an interface proxy arranged to manage the availability of features and communication to the respective entity. The resource management system includes a managing device connectable through a physical interface to at least one entity comprising a number of feature devices. The interface proxy is associated with at least one entity for cooperation with the apparatus; and the interface proxy is adapted to handle resource allocation of the feature devices.
    Type: Application
    Filed: November 1, 2006
    Publication date: November 8, 2007
    Applicant: SONY ERICSSON MOBILE COMMUNICATIONS AB
    Inventor: Stefan Bengt Gustavsson
  • Publication number: 20070249613
    Abstract: The use of tetrahydrofolate, methylene-tetrahydrofolate and/or methyl-tetrahydrofolate, and at least one multi-targeting antifolate, for the manufacture of a pharmaceutical composition for the treatment of cancer is disclosed. By combining the multi-targeting anti-folate with tetrahydrofolate, methylene-tetrahydrofolate and/or methyl-tetrahydrofolate, it is possible to remarkably reduce toxic side-effects without diminishing the anti-tumour action of the drugs. A pharmaceutical composition, a kit comprising the pharmaceutical composition as well as a method for the treatment of cancer are also disclosed.
    Type: Application
    Filed: December 22, 2004
    Publication date: October 25, 2007
    Applicant: BIOFOL AB
    Inventors: Bengt Gustavsson, Goran Carlsson
  • Patent number: 7256347
    Abstract: A control cord for connecting an auxiliary device to a portable electronic device is provided. The control cord includes a flexible longitudinal housing and a plurality of electrical conductors extending from one end of the housing to which the auxiliary device will be connected, to an other end of the housing. In addition, the control cord includes a connector affixed to the other end of the housing and configured to connect the plurality of electrical conductors to the portable electronic device to enable operation of the portable electronic device in cooperation with the auxiliary device. The connector includes at least one terminal configured to be received by the portable electronic device, and the at least one terminal provides a control input to the portable electronic device, the control input being derived from physical manipulation of the housing.
    Type: Grant
    Filed: December 14, 2005
    Date of Patent: August 14, 2007
    Assignee: Sony Ericsson Mobile Communications AB
    Inventor: Stefan Bengt Gustavsson
  • Patent number: 4932937
    Abstract: A vessel for safe handling of substances and having a first connection member through which the interior of the vessel is accessible by a device, e.g., an injection syringe, for removing or adding material thereto. At least a part of the vessel is expandable and contractable. The vessel is further provided with a second connection member, which is interconnected or interconnectable with the first connection inside the vessel. The second connection member is connectable to a further vessel outside the vessel, so that substance can be transferred directly from the injection syringe to said further vessel via the first and second connection members.
    Type: Grant
    Filed: August 25, 1988
    Date of Patent: June 12, 1990
    Inventors: Bengt Gustavsson, Lars-Erik Linder